Diligence memo · auto-generated · as of July 2, 2026
Respirics Inc
Respirics Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Respirics Inc operates in Pharmaceuticals, based in RALEIGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Respirics Inc has raised $4.2M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.7M on 2010-04-16.
Most recent recorded round closed around 2010-08-27.
Valuation (modeled)modeled
Provath models Respirics Inc at approximately $5.6M (range $111K–$44M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.09× the median modeled value of Seed Pharmaceuticals companies in 2010–2012 (58 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 15.8 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 25.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 39% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 10% of those peers.
Closest niche peers: First China Pharmaceutical Group, Inc., MediQuest Holdings LLC, Ampla Pharmaceuticals Inc, Biomimetix Pharmaceutical, Inc., Prexa Pharmaceuticals Inc.
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.